Northeast Pharmaceutical gains approval for efavirenz raw material

Northeast Pharmaceutical Group Co., Ltd. (SZSE:000597) announced that it has received approval from the National Medical Products Administration for its Efavirenz chemical raw material listing application. The approval, registered under number Y20230001004, signifies that the company's production processes and quality control meet national standards, allowing the raw material to be used in domestic formulations. The registration is valid for 18 months. Efavirenz is a key drug for treating HIV-1 infections, acting as a non-nucleoside reverse transcriptase inhibitor. While the approval is expected to enhance the company's product portfolio and market competitiveness, the company advises investors to be cautious due to uncertainties surrounding GMP compliance inspections, policy changes, and market conditions.